Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
作者信息
Hayette Sandrine, Chabane Kaddour, Tchirkov Andrei, Berger Marc G, Nicolini Franck E, Tournilhac Olivier
出版信息
Haematologica. 2009 Sep;94(9):1324-6. doi: 10.3324/haematol.2009.007864.
Abstract
摘要
相似文献
1
Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.在一名对伊马替尼耐药但对达沙替尼敏感的双表型急性白血病患者中检测BCR-ABL激酶结构域中的12个核苷酸插入。
Haematologica. 2009 Sep;94(9):1324-6. doi: 10.3324/haematol.2009.007864.
2
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.伊马替尼治疗失败后接受第二代酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的长期预后可通过BCR-ABL激酶结构域突变的体外敏感性来预测。
Blood. 2009 Sep 3;114(10):2037-43. doi: 10.1182/blood-2009-01-197715. Epub 2009 Jun 30.
3
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.在伊马替尼治疗失败后接受二线达沙替尼或尼洛替尼治疗的慢性髓性白血病患者中，对检测BCR-ABL激酶结构域突变的不同方法进行的合作评估。
Haematologica. 2009 Sep;94(9):1227-35. doi: 10.3324/haematol.2009.006981. Epub 2009 Jul 16.
4
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.已经携带对伊马替尼耐药的Bcr-Abl激酶结构域突变的费城染色体阳性患者，发生与对二线或三线酪氨酸激酶抑制剂耐药相关的其他突变的可能性更高。
Blood. 2009 Sep 3;114(10):2168-71. doi: 10.1182/blood-2009-01-197186. Epub 2009 Jul 9.
5
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗停止后突变型 BCR-ABL 阳性克隆的动力学。
Haematologica. 2011 Mar;96(3):360-6. doi: 10.3324/haematol.2010.030999. Epub 2010 Dec 6.
6
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.ON012380，一种假定的BCR-ABL激酶抑制剂，在伊马替尼耐药细胞中具有独特的作用机制。
Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28.
7
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.达沙替尼用于治疗费城染色体阳性白血病。
Expert Opin Investig Drugs. 2007 May;16(5):679-87. doi: 10.1517/13543784.16.5.679.
8
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.达沙替尼 100mg 每日治疗可强效、短暂地抑制 BCR-ABL，对于对伊马替尼耐药、治疗反应欠佳或不耐受的慢性期慢性髓性白血病患者，可迅速并持久地获得细胞遗传学反应，且无进展生存率较高。
Haematologica. 2010 Feb;95(2):232-40. doi: 10.3324/haematol.2009.011452.
9
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.达沙替尼用于伊马替尼耐药的费城染色体阳性白血病。
N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229.
10
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.成人费城染色体阳性急性淋巴细胞白血病的当前治疗选择。
Leuk Lymphoma. 2010 Feb;51(2):188-98. doi: 10.3109/10428190903452834.
引用本文的文献
1
The Emergence of a Novel Insertional Mutation in the BCR::ABL/p210 Oncogene in B-Cell Acute Lymphoblastic Leukemia (B-ALL) Correlates with the Development of Resistance to Several Tyrosine Kinase Inhibitors.B细胞急性淋巴细胞白血病（B-ALL）中BCR::ABL/p210癌基因新插入突变的出现与对多种酪氨酸激酶抑制剂耐药性的产生相关。
Acta Naturae. 2025 Apr-Jun;17(2):52-57. doi: 10.32607/actanaturae.27539.
2
Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.在一名Ph+急性淋巴细胞白血病患者中检测到的一种新的BCR::ABL1 p.I293_K294insSSLRD突变对阿塞西尼布耐药。
Ann Hematol. 2025 Feb;104(2):1117-1126. doi: 10.1007/s00277-024-06142-8. Epub 2025 Jan 7.
3
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.新型 K294RGG 插入突变位于 BCR-ABL 激酶结构域，导致伊马替尼耐药：慢性髓细胞白血病急变期患者中克隆进化的连续分析。
Int J Hematol. 2011 Feb;93(2):237-242. doi: 10.1007/s12185-011-0766-2. Epub 2011 Jan 25.
本文引用的文献
1
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.BCR-ABL可变剪接作为伊马替尼耐药的常见机制：来自分子动力学模拟的证据
Mol Cancer Ther. 2008 Dec;7(12):3834-41. doi: 10.1158/1535-7163.MCT-08-0482. Epub 2008 Dec 3.
2
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.接受激酶抑制剂治疗的慢性髓性白血病患者中，BCR-ABL激酶结构域存在内含子衍生的插入/截断突变。
J Mol Diagn. 2008 Mar;10(2):177-80. doi: 10.2353/jmoldx.2008.070128. Epub 2008 Feb 14.
3
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.伊马替尼血液学或细胞遗传学耐药之前BCR-ABL突变克隆的动态变化。
Haematologica. 2008 Feb;93(2):186-92. doi: 10.3324/haematol.11993. Epub 2008 Jan 26.
4
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.27例携带T315I BCR-ABL突变的甲磺酸伊马替尼耐药慢性髓性白血病患者的临床结局
Haematologica. 2007 Sep;92(9):1238-41. doi: 10.3324/haematol.11369.
5
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Leukemia. 2006 Nov;20(11):2057-60. doi: 10.1038/sj.leu.2404400. Epub 2006 Sep 28.
6
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.甲磺酸伊马替尼治疗的慢性髓性白血病患者中BCR-ABL突变的频率及临床意义
Leukemia. 2006 Oct;20(10):1767-73. doi: 10.1038/sj.leu.2404318. Epub 2006 Jul 20.
7
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).89例甲磺酸伊马替尼耐药慢性粒细胞白血病患者的突变状态及临床结局：来自法国慢性粒细胞白血病协作组（Fi(phi)-LMC GROUP）的回顾性分析
Leukemia. 2006 Jun;20(6):1061-6. doi: 10.1038/sj.leu.2404236.
8
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.监测接受酪氨酸激酶抑制剂治疗的慢性粒细胞白血病患者：关于统一当前检测BCR-ABL转录本和激酶结构域突变方法以及结果表达的综述与建议。
Blood. 2006 Jul 1;108(1):28-37. doi: 10.1182/blood-2006-01-0092. Epub 2006 Mar 7.
9
Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.评估和随访T315I突变的BCR-ABL转录本比例可指导慢性粒细胞白血病患者做出合适的治疗决策。
Leuk Res. 2005 Sep;29(9):1073-7. doi: 10.1016/j.leukres.2005.02.006. Epub 2005 Mar 23.
10
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.伊马替尼一线治疗时细胞遗传学耐药的慢性髓性白血病慢性期晚期患者的ABL突变与进展为急变期的可能性增加及生存期缩短相关：一项由GIMEMA慢性髓性白血病工作组开展的研究
J Clin Oncol. 2005 Jun 20;23(18):4100-9. doi: 10.1200/JCO.2005.05.531. Epub 2005 May 2.
Zotero 插件